GlassScriptPhysician profile
Diana Pham
NPI 1346627312
$7,286.62
in general payments reported to CMS, 2019-2025
39 companies · $1,946 in 2025
The $1,946 reported for 2025 was more than what 93% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $545 · 2022: $1,467 · 2023: $1,965 · 2024: $1,364 · 2025: $1,946.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,274.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,229.88 | 2022-2025 | Farxiga, Breztri, Fasenra |
| Abbvie INC. | $836.29 | 2021-2025 | |
| Lilly USA, LLC | $660.28 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $403.11 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $328.98 | 2023-2025 | Caplyta |
| Lundbeck LLC | $318.86 | 2023-2025 | Rexulti |
| Glaxosmithkline, LLC. | $293.26 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $249.91 | 2021-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $243.98 | 2021-2023 | Gattex, Trintellix |
| Novo Nordisk INC | $235.18 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Teva Pharmaceuticals USA, INC. | $231.72 | 2023-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Nestle Healthcare Nutrition INC. | $207.55 | 2022-2023 | |
| Aimmune Therapeutics, INC. | $181.59 | 2024-2025 | Vowst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $176.84 | 2022-2024 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $176.21 | 2021-2023 | Steglujan, Steglatro, Belsomra |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diana Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.